Anxioselective anxiolytics: can less be more?
by
Basile AS, Lippa AS, Skolnick P.
DOV Pharmaceutical, Inc.,
433 Hackensack Avenue, Hackensack,
NJ 07601, USA.
Eur J Pharmacol. 2004 Oct 1;500(1-3):441-51


ABSTRACT

Benzodiazepines remain widely used for the treatment of anxiety disorders despite a side-effect profile that includes sedation, myorelaxation, amnesia, and ataxia, and the potential for abuse. gamma-Aminobutyric acid(A) (GABA(A)) receptor partial agonists, subtype-selective agents, and compounds combining both of these features are being developed in an attempt to achieve benzodiazepine-like efficacy without these potentially limiting side effects. This article reviews the nonclinical and clinical studies of "anxioselective" anxiolytics that target GABA(A) receptors and discusses potential mechanisms subserving an anxioselective profile.
Benzodiazepines
Anxiety resources
Future anxiolytics
Anxiety and depression
Better anti-anxiety drugs
Anxiolytics/antidepressants
Neurobiology and genetics of anxiety
GABAergic dysfunction in mood disorders


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family